CAPN2-Targeting Agent AMX0114 Shows Safe Profile in Phase 1 LUMINA Trial of ALS Marco Meglio

Published Date: 24 Dec 2025

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Make the Diagnosis: Can You Explain Her Rash and Conjunctival Injection?

2.

Health of Myeloma Patient's Marriage Tied to Recovery After Transplant

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

In-person and Virtual Palliative Care Are Both Beneficial for Advanced Lung Cancer Patients.

5.

From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot